Short Paper: Seroepidemiology of SARS-CoV-2 infections in an urban Nicaraguan population

Fredman González¹*, Nadja A. Vielot²*, Michael Sciaudone³, Christian Toval-Ruíz¹, Lakshmanane

Premkumar⁴, Lester Gutierrez¹, Edwing Centeno Cuadra¹, Patricia Blandón¹, Aravinda M. de Silva⁴,

Rebecca Rubinstein, Natalie Bowman³, Sylvia Becker-Dreps²*, Filemon Bucardo¹*

1. Center for Infectious Diseases Research, National Autonomous University of Nicaragua – León, León,

Nicaragua

2. Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North

Carolina, USA

3. Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North

Carolina, USA

4. Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel

Hill, North Carolina, USA

5. School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

* = signifies equal contribution as first and senior authors

Corresponding Author:

Filemon Bucardo, PhD

Center for Infectious Diseases Research

National Autonomous University of Nicaragua, León

León, Nicaragua

Fili_bucardo@hotmail.com

+505 8904 0938

Abstract word count: 47 words

Manuscript word count: 1,441 words

Running title: SARS-CoV-2 seroepidemiology in Nicaragua

1 **ABSTRACT**

- 2 In a Nicaraguan population-based cohort, SARS-CoV-2 seroprevalence was 34%, with higher prevalence
- 3 in children compared to adults. Having a seropositive household member was associated with a two-fold
- probability of individual seropositivity, suggesting a role for household transmission. Co-morbidities and 4
- 5 preventive behaviors were not associated with SARS-CoV-2 seroprevalence.

Keywords: SARS-CoV-2, COVID-19, seroprevalence, epidemiology, Nicaragua

INTRODUCTION

6

7 SARS-CoV-2 transmission continues globally. The pandemic is now entering a prolonged phase, potentially causing multiple waves of infection in populations that have not attained community 8 9 immunity. In this new phase, information on SARS-CoV-2 seroprevalence in different populations is 10 urgently needed to understand the magnitude of SARS-CoV-2 spread in previous waves, predict future waves, and measure the risk of re-infection in previously exposed persons. Furthermore, little is known 11 12 about SARS-CoV-2 seroprevalence in different age groups or in individuals with factors which place 13 them at higher risk for poor outcomes. 14 Prior studies have measured SARS-CoV-2 seroprevalence in hotspots that were heavily impacted by 15 infections in the first wave of the pandemic (Dec 2019-May 2020). In Wuhan, China, where the pandemic 16 originated, seroprevalence was 4% in May 2020; in Lombardy, Italy, seroprevalence among blood donors reached 23% by April 2020. 2,3 This wide range of estimates suggests that geographical, social, and 17 18 economic differences, as well as the implementation of containment measures can greatly affect exposure 19 to and infection with SARS-CoV-2. 20 Even less is known in low-and middle-income countries (LMICs), which have limited resources to 21 perform molecular detection of SARS-CoV-2 in real time, complicating estimates of infection incidence 22 and individual disease risk. Furthermore, LMICs have fewer resources to support remote work and 23 schooling, hygiene measures, and vaccines, and households are often multi-generational. The goal of this 24 study was to estimate the seroprevalence of SARS-CoV-2 in a population-based sample in León, 25 Nicaragua since SARS-CoV-2 infections were first reported in March 2020. These data on the prevalence 26 of past infections can be used to guide public health recommendations and inform the need for 27 continuation of SARS-CoV-2 prevention measures.

METHODS

28

29

Study Design and Population

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

The Sapovirus-Associated Gastro-Enteritis (SAGE) study is a population-based birth cohort study in León, Nicaragua, described previously. This cohort provided a platform to access a sample of all ages to understand the seroprevalence of SARS-CoV-2 in a Latin American context, and to examine differences in participant characteristics by evidence of prior infection. The study population included high-income families in the city center and low-income families in peri-urban neighborhoods, creating a scientificallyinformative gradient to evaluate socioeconomic and environmental risk factors for SARS-CoV-2 infection. Starting in July 2020, we contacted the household members of cohort children (both adults and children) and offered participation in this study. We also offered participation in the study for cohort children, including those who had reached 36 months of age. The study was approved by the Institutional Review Boards of the National Autonomous University of Nicaragua, León (UNAN-León, acta No. 170, 2020) and the University of North Carolina at Chapel Hill (Study #: 20-2126). All adult participants provided informed consent, and parental permission was required for children's participation in the study. In September and October 2020, we collected baseline demographic and health history data and collected blood from all participants for baseline SARS-CoV-2 serology. The current report summarizes the seroprevalence of SARS-CoV-2, stratifying by co-morbidities and sociodemographic factors. Specimen Collection and Laboratory Methods SARS-CoV-2 infection induces the production of antibodies (Ab) against the spike protein and nucleocapsid protein, with most patients seroconverting within 2 weeks of symptom onset.⁵ We used an in-house enzyme-linked immunosorbent (ELISA) assay to measure antibodies (IgG, IgA, and IgM) to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, which we have previously shown to be highly sensitive and specific for detecting antibodies for at least six months among individuals experiencing symptomatic infection.⁵ The spike RBD-based assay does not cross-react with common endemic coronaviruses, and the magnitude of RDB antibody titers correlate with neutralizing antibody titers, currently the best correlate of protection against infection.⁵ In brief, ELISA plates (Greiner Bio-One #655061) were coated with 4µg/ml of the RBD antigen. Heat-inactivated serum diluted at 1:40 was

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

subsequently added and alkaline phosphate conjugated secondary goat anti-human Abs (anti-IgG [Sigma], anti-IgA [Ab cam], and anti-IgM [Sigma]) were added at 1:2,500 dilution for detection. The immunologic reaction was developed with para-Nitrophenyl phosphate substrate (SIGMA). The optical density (OD) was measured after 15 min at 405nm. A serum was considered positive if the positive/negative (P/N) ratio between the serum OD and the negative-control OD was ≥2.57, to ensure 99.5% specificity per CDC guidelines.6 Statistical Analysis We analyzed cross-sectional data using frequencies and percentages to characterize SARS-CoV-2 seroprevalence, stratified by sex, age group, smoking status, presence of comorbidities, and socioeconomic characteristics of the household. We implemented generalized estimating equations to estimate prevalence ratios (PRs) comparing seropositivity proportion by select individual and household characteristics, accounting for clustering of individuals within households. **RESULTS** Between September and October 2020, we enrolled 1,847 participants from 295 households. Of 1,351 individuals who provided serum samples, 456 were seropositive for SARS-CoV-2 (34%). In 192 households (65%), at least one household member had SARS-CoV-2 antibodies at the time of enrollment. In these households, the median number of seropositive members was 2 (interquartile range: 1, 3), and the maximum number was 9. Women were less likely to be seropositive than men (PR: 0.90, 95% CI: 0.77, 1.06), and younger age groups were more likely to be seropositive than older age groups (PR: 0.93, 95% CI: 0.88, 0.99), with approximately half of seropositive individuals younger than 15 years (Table). Smoking and the presence of comorbidities was associated with a lower prevalence of seropositivity, though several of these associations are imprecise due to small numbers. Seropositivity was not associated with physical distancing or masking behavior, nor with economic status of the household. Seropositivity was twice as

high among individuals who lived with another seropositive household member (PR: 1.97, 95% CI: 1.43,

2.69).

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

DISCUSSION

Our results show a high rate of seropositivity for SARS-CoV-2 antibodies in a Nicaraguan populationbased cohort. This suggests the actual number of SARS-CoV-2 infections in Nicaragua was higher than official reports, which might be explained by a high rate of asymptomatic and mild cases that did not seek medical attention, or by limited testing of patients who received medical attention. Our seroprevalence results are similar to those of another study from Brazil, and those reported from SARS-CoV-2 hot spots in high income countries, such as Massachusetts and Northern Italy, although the Massachusetts study was not carried out in a population-based cohort. ^{2,8} In these studies, the seroprevalence of SARS-CoV-2 antibodies was higher than expected based on the reported incidence of symptomatic SARS-CoV-2 infections in the area. It is possible we slightly underestimated the actual number of SARS-CoV-2 cases because of the high P/N cutoff used to ensure high assay specificity. A recent study has shown anti-SARS-CoV-2 spike protein IgG remains detectable in most cases for at least 6 months after symptomatic infection, and our data were collected within 6 months of the first reported SARS-CoV-2 case in Nicaragua. A recent cross-sectional study of Nicaraguan health care workers (HCWs) conducted over a one-month period found that 30% of participants had active SARS-CoV-2 infection, indicating that seroprevalence among Nicaraguan health care workers is likely higher than in the general population.¹⁰ About half of SARS-CoV-2 infected HCWs were asymptomatic, and, similar to our results, men were more likely to have been infected. Use of personal protective equipment is critical among HCWs, both to prevent contracting SARS-CoV-2 from infected patients and to prevent transmitting SARS-CoV-2 to patients, particularly when the HCW is asymptomatic. We identified high seroprevalence among younger age groups, particularly in children between 5 and 14 years of age (42%). Age-based differences in seropositivity were observed in Brazil and Italy.^{2,7} however. they were more pronounced in our population. High seropositivity in children might be due to continued

operation of public schools throughout the epidemic. As children are more likely to experience mild symptoms than adults, ¹¹ this finding suggests that school-aged children may contribute to active transmission, and controlling infections in this sub-population is essential to reduce the spread of SARS-CoV-2. We also found that most individuals reported practicing strict physical distancing or masking behavior outside of the home, though this did not have a significant impact on the seroprevalence.

Transmission within the home may have been more important. ¹² The median household size in our sample was 7 members, with a maximum of 26 members. Indeed, SARS-CoV-2 seropositivity was two-fold more frequent for individuals with a seropositive household member as compared to individuals who did not have a seropositive household member.

In conclusion, we found a high SARS-CoV-2 seroprevalence in this Nicaraguan population and confirmed that reported SARS-CoV-2 case counts underestimated the true number of infections. We also show that this population has not yet attained the theoretical community immunity threshold, and so continued containment measures are necessary. In the future, this population could be followed to understand the risk of recurrent infection, and repeated seroprevalence measurements could provide further information on transmission dynamics.

ACKNOWLEDGEMENTS

We greatly appreciate Yorling Picado, Nancy Corea Munguia, Franco Soto, and the SAGE field team for their important contributions to this study.

FUNDING

This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID, grant number R01AI127845 to SBD, K24AI141744 to SBD). FG is supported by an international research capacity-building award from the Fogarty International Center (grant number D43TW010923).

CONFLICTS OF INTEREST

The authors report no conflicts of interest.

Table. Characteristics associated with SARS-CoV-2 seropositivity of individuals in León, **Nicaragua** Seronegative Seropositive (n=895)(n=456)Prevalence Ratio (95% Confidence Interval) Individual and household n (%) n (%) characteristics Sex Male 350 (63.8) 199 (36.2) 0.90(0.77, 1.06)Female 545 (68.0) 257 (32.0) Age group in years (n=1,325)0-4218 (64.3) 121 (35.7) 5-14 145 (59.4) 99 (40.6) 15-29 263 (68.0) 124 (32.0) 0.93 (0.88, 0.99) 30-49 165 (72.7) 62 (27.3) 50-69 81 (73.0) 30 (27.0) 70 +10 (52.6) 9 (47.4) Smoking status (n=782)^a 28 (27.2) Ever smoker 75 (72.8) 0.85 (0.62, 1.18) Never smoker 465 (68.5) 214 (31.5) Presence of comorbidities $(n=1,312)^{b}$ No 788 (66.6) 396 (33.4) 0.88(0.67, 1.15)Yes 88 (68.8) 40 (31.2) Diabetes (n=128) No 68 (70.1) 29 (29.9) 1.12 (0.62, 2.01) Yes 20 (64.5) 11 (35.5) Hypertension (n=128) No 41 (66.1) 21 (33.9) 0.85 (0.51, 1.44) Yes 47 (71.2) 19 (28.8) Malignancy (n=128) No 86 (68.8) 39 (31.2) 1.20 (0.28, 5.01) Yes 2 (66.7) 1 (33.3) Autoimmune disease (n=128) No 86 (68.3) 40 (31.7) n/a Yes 2 (100.0) 0(0.0)Physical distancing and masking behavior $(n=1.325)^{c}$ Strict 797 (66.7) 398 (33.3) Moderate 31 (56.4) 24 (43.6) 1.06 (0.91, 1.22) None 49 (65.3) 26 (34.7) Crowding index (n=1,212)Fewer than 2.7 people per bedroom 535 (66.1) 274 (33.9) 0.91 (0.73, 1.15) 2.7 or more people per bedroom 277 (68.7) 126 (31.3) Poverty index $(n=1,212)^d$

378 (67.0)

186 (33.0)

0.96(0.82, 1.11)

Not poor

Poor	349 (65.6)	183 (34.4)	
Extremely poor	85 (73.3)	31 (26.7)	
Household member is seropositive			
No	323 (36.1)	74 (16.2)	1 07 (1 42 2 (0)
Yes	572 (63.9)	382 (83.8)	1.97 (1.43, 2.69)

^aSmoking status assessed among participants older than 13 years of age.

^bDiagnosed by medical professional as reported by participant, including diabetes, hypertension, obesity, malignancy, and autoimmune disease.

^cStrict = never left the house since first cases reported or occasionally leaves house and always uses a mask;

Moderate=Occasionally leaves the house and sometimes uses a mask; None = Occasionally leaves the house and never uses a mask or no distancing or quarantine behavior.

^dPoverty index calculated based on presence of basic needs, including household sanitation, education, economic dependency, and household crowding.

REFERENCES

- COVID-19 Map Johns Hopkins Coronavirus Resource Center.
 https://coronavirus.jhu.edu/map.html. Accessed February 9, 2021.
- Percivalle E, Cambiè G, Cassaniti I, et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. Euro Surveill. 2020;25(24). doi:10.2807/1560-7917.ES.2020.25.24.2001031
- 3. Xu X, Sun J, Nie S, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. *Nat Med.* 2020;26(8):1193-1195. doi:10.1038/s41591-020-0949-6
- 5. Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Sci Immunol*. 2020;5(48). doi:10.1126/sciimmunol.abc8413
- Interim Guidelines for COVID-19 Antibody Testing. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html.
 Published February 11, 2020. Accessed February 9, 2021.
- Silva AAM da, Lima-Neto LG, Azevedo C de MPES de, et al. Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão. *Rev Saude Publica*. 2020;54:131. doi:10.11606/s1518-8787.2020054003278
- Naranbhai V, Chang CC, Beltran WFG, et al. High Seroprevalence of Anti-SARS-CoV-2
 Antibodies in Chelsea, Massachusetts. *J Infect Dis*. 2020;222(12):1955-1959.
 doi:10.1093/infdis/jiaa579

- Lumley SF, Wei J, O'Donnell D, et al. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. *Clin Infect Dis*. January 2021. doi:10.1093/cid/ciab004
- Huete-Pérez JA, Cabezas-Robelo C, Páiz-Medina L, Hernández-Álvarez CA, Quant-Durán C,
 McKerrow JH. First report on prevalence of SARS-CoV-2 infection among health-care workers in
 Nicaragua. PLoS One. 2021;16(1):e0246084. doi:10.1371/journal.pone.0246084
- 11. Syangtan G, Bista S, Dawadi P, et al. Asymptomatic SARS-CoV-2 Carriers: A Systematic Review and Meta-Analysis. *Front Public Health*. 2020;8:587374. doi:10.3389/fpubh.2020.587374
- Signorelli C, Odone A, Stirparo G, et al. SARS-CoV-2 transmission in the Lombardy Region: the increase of household contagion and its implication for containment measures. *Acta Biomed*.
 2020;91(4):e2020195. doi:10.23750/abm.v91i4.10994